Episode 1674 • • 47:01 - 50:09
1674: We're Working!
FDA Approval of Eli Lilly Alzheimer's Drug Kisunla
The FDA has approved Eli Lilly's new Alzheimer's medication, Kisunla (donanemab), designed to slow the progression of early-stage dementia. The hosts discuss the drug's $695-per-vial cost and speculate on its potential use for high-profile political figures showing signs of cognitive decline.